Monograph Title Sort descending | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
DOXORUBICIN HYDROCHLORIDE | ASSAY | USPNF Online | Online | 26-Apr-2024 | 1-May-2024 | NA | NA | In Procedure/System suitability solution: Add link to USP Store for USP Epirubicin Hydrochloride RS |
DOXORUBICIN HYDROCHLORIDE FOR INJECTION | IMPURITIES/Organic Impurities | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Analysis: Change P = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: P = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) |
DOXORUBICIN HYDROCHLORIDE FOR INJECTION | ASSAY/Procedure | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Analysis: Change P = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: P = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) |
DOXORUBICIN HYDROCHLORIDE INJECTION | ASSAY/Procedure | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Analysis: Change P = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: P = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) |
DOXORUBICIN HYDROCHLORIDE INJECTION | IMPURITIES/Organic Impurities | USPNF 2022 Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Analysis: Change P = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: P = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) |
DOXYCYCLINE CAPSULES | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide… Read More |
DOXYCYCLINE FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide… Read More |
DOXYCYCLINE HYCLATE | CHEMICAL INFORMATION | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | Change 1025.87 to: 1025.88 |
DOXYCYCLINE HYCLATE | IMPURITIES/Organic Impurities | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | In Table 2, footnote b: Change (4S,4aR,5S,5aR,6R,12aS)-2-Acetyl-4-(dimethylamino)-4a,5a,6,12a-tetrahydro-3,5,10,12,12a-pentahydroxy-6-methyl-tetracene-1,11-dioxo-2-naphthacenecarboxamide. to: (4S,4aR,5S,5a… Read More |
DOXYCYCLINE HYCLATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change 480.13 to: 480.90 |
DOXYCYCLINE HYCLATE CAPSULES | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide… Read More |
DOXYCYCLINE HYCLATE DELAYED-RELEASE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide… Read More |
DOXYCYCLINE HYCLATE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide… Read More |
DOXYCYCLINE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change (4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide… Read More |
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES | PERFORMANCE TESTS | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In Dissolution 〈711〉/Test for dutasteride/Tier 2/Medium: Change 10 g/L of cetyltrimethylammonium bromide and 750,000 USP units of activity/mg of pepsin, purified in 0.1 N hydrochloric acid; 900 mL to: Dissolve 10 g of… Read More |
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In USP Reference Standards 〈11〉/USP Dihydrodutasteride RS: Change N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide. to: N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androstane-17β-carboxamide. |
ECONAZOLE NITRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In USP Econazole Related Compound C RS: Change 1-(4-Chlorobenzyl)-3-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazol-3-ium nitrate (salt). C25H21Cl14N3O4 569.… Read More |
ENSULIZOLE | IDENTIFICATION | USPNF Online | Online | 29-Mar-2024 | 1-Apr-2024 | NA | NA | In B.: Change The retention time of the major peak of the Sample solution exhibits maxima and minima at the same wavelengths as those of the Standard solution, as obtained in the Assay. to: The retention time of the major… Read More |
ENZACAMENE | ASSAY/Procedure | USPNF Online | Online | 28-Oct-2022 | 1-Dec-2022 | NA | NA | In Analysis: Change CU = concentration of enzacamene in the Sample solution (mg/mL) to: CU = concentration of Enzacamene in the Sample solution (mg/mL) |
ERYTHROMYCIN DELAYED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution 〈711〉 | USPNF Online | Online | 31-Mar-2023 | 1-Apr-2023 | NA | NA | In Test 1: Change Buffer stage Medium: 0.05 M pH 6.8 phosphate buffer (see Reagents, Indicators, and Solutions—Buffer Solutions) to: Buffer stage Medium: 0.05 M pH 6.8 phosphate buffer (see Reagents,… Read More |
ERYTHROMYCIN ETHYLSUCCINATE FOR ORAL SUSPENSION | Identification | USPNF Online | Online | 31-Mar-2023 | 1-Apr-2023 | NA | NA | Change Proceed as directed in the Identification test under Erythromycin Ethylsuccinate Oral Suspension, beginning with “Prepare a Standard solution.” to: Prepare a Standard solution of USP Erythromycin Ethylsuccinate RS in methanol… Read More |
ERYTHROMYCIN ETHYLSUCCINATE FOR ORAL SUSPENSION | Assay | USPNF Online | Online | 31-Mar-2023 | 1-Apr-2023 | NA | NA | Change Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed in the Assay under Erythromycin Ethylsuccinate Oral Suspension. to: Constitute Erythromycin Ethylsuccinate for Oral… Read More |
ESCITALOPRAM TABLETS | ASSAY/Procedure | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Buffer: Change Adjust with 1 N sodium hydroxide VS to a pH of 5.2. to: Adjust with 1 N sodium hydroxide to a pH of 5.2. |
ESCITALOPRAM TABLETS | PERFORMANCE TESTS/Dissolution 〈711〉 | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Test 1/Medium: Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL AND In Test 2/Medium: Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL |
FELODIPINE | IMPURITIES/Organic Impurities | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | NA | Change Buffer, Mobile phase, System suitability solution, Standard solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay. to: Buffer, Mobile phase… Read More |
FLUOCINOLONE ACETONIDE | Organic Impurities | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | In Acceptance criteria/Total impurities: Change NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone acetonide from the Standard solution. to: NMT 2.5%. Disregard any peak below 0.05% of the peak area of… Read More |
FLURAZEPAM HYDROCHLORIDE | USP REFERENCE STANDARDS 〈11〉 | USPNF Online | Online | 23-Feb-2024 | 1-Mar-2024 | NA | NA | In USP Flurazepam Related Compound C RS: Change 5-Chloro-2-(2-diethylaminoethyl(amino)-2′-fluorobenzophenone hydrochloride. to: 5-Chloro-2-(2-diethylaminoethylamino)-2′-fluorobenzophenone hydrochloride. |
FLUTICASONE PROPIONATE NASAL SPRAY | IMPURITIES/Organic Impurities | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | In Analysis: Change Samples: System suitability solution, Identification solution, and Sample solution to: Samples: Identification solution and Sample solution |
FLUTICASONE PROPIONATE NASAL SPRAY | OTHER COMPONENTS/Content of Phenylethyl Alcohol | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Sample solution: Change Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask. Add about 40 mL of Diluent, and sonicate for 10 min until the supernatant is clear. Use the clear supernatant for analysis. to: Transfer 1.0 g of the… Read More |
FLUVOXAMINE MALEATE TABLETS | ASSAY/Procedure | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Solution A: Change 8 g/L of 1-pentanesulfonic acid sodium salt and 1 g/L of monobasic potassium phosphate in water. to: 8 g/L of 1-pentanesulfonic acid sodium salt and 1.1 g/L of monobasic potassium phosphate in water. |
FORSKOHLII | COMPOSITION/Content of Forskolin | USPNF Online | Online | 29-Jul-2022 | 1-Aug-2022 | NA | NA | In Chromatographic system: Change Column: 4.6-mm × 25-cm; 5-µm, 100 Å to: Column: 4.6-mm × 25-cm; 5-µm, 100 Å; packing L1 |
FOSAMPRENAVIR CALCIUM TABLETS | PERFORMANCE TESTS | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Dissolution 〈711〉/Medium: Change 26.7 g/L of sodium acetate trihydrate in water. Add 133 mL of glacial acetic acid to this solution, and then dilute with water to 10 L; 900 mL. to: 0.02 M sodium acetate buffer, pH 3.5, prepared as follows.… Read More |
GLUCAGON | PROCESS-RELATED IMPURITIES AND OTHER COMPONENTS | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | In Acetic Acid in Peptides/Analysis: Change CSPA = concentration of potassium acetate in each of the Standard solutions (mg/mL) to: CSPA = concentration of potassium acetate in each of the … Read More |
GLYCYL-L-TYROSINE | IMPURITIES/Related Compounds | USPNF Online | Online | 24-Feb-2023 | 1-Jun-2023 | NA | NA | In Buffer solution: Change Dissolve 6.84 g of potassium phosphate in 1000 mL of water. to: Dissolve 6.84 g of monobasic potassium phosphate in 1000 mL of water. |
HOMATROPINE HYDROBROMIDE | CHEMICAL INFORMATION | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | Change 356.25 to: 356.26 AND Change 1αH,5αH-Tropan-3α-ol mandelate (ester) hydrobromide to: (1R,3r,5S)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-2-phenylacetate hydrobromide |
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS | ASSAY/Procedure | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In Buffer: Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1. |
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS | IMPURITIES/Limit of Homatropine Hydrobromide and Related Substances | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In Buffer: Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1. |
IBUPROFEN ORAL SUSPENSION | PERFORMANCE TESTS/Dissolution <711> | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | In Analysis: Change Result = (RU/RS) x CS x V x (D/WU) x (1/L) x 100 RU = peak area ratio of ibuprofen to benzophenone from the … Read More |
IODIXANOL INJECTION | IMPURITIES | USPNF Online | Online | 23-Feb-2024 | 1-Mar-2024 | NA | NA | In Organic Impurities, Procedure 2/footnote 4: Change 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl](acetylimino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]-2-hy… Read More |
IODIXANOL INJECTION | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 23-Feb-2024 | 1-Mar-2024 | NA | NA | In USP Reference Standards 〈11〉/USP Iodixanol Related Compound E RS: Change 5-[[3-[[3-[[(2,3-Dihydroxypropyl)amino]carbonyl]-5- [[amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl]-(acetylimino)]-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-… Read More |
IPRATROPIUM BROMIDE INHALATION SOLUTION | IMPURITIES | USPNF Online | Online | 29-Mar-2024 | 1-Apr-2024 | NA | NA | In Organic Impurities: Change Column: 4.6-mm × 25-µm; 5-µm packing L1 to: Column: 4.6-mm × 25-cm; 5-µm packing L1 |
IRINOTECAN HYDROCHLORIDE INJECTION | DEFINITION | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | NA | Change NTL 90.0% and NMT 110.0% to: NLT 90.0% and NMT 110.0% |
ISOBUTYL ALCOHOL | ASSAY/Procedure | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | In Analysis: Change rS = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the Reference solution to: rT = sum of all the peaks except those… Read More |
ISOFLURANE | IMPURITIES/Organic Impurities | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Analysis: Change Result = (rU/rS) × CS × (1/F) to: Result = (rU/rS) × CF × (1/F) AND Change CS… Read More |
ISOSORBIDE MONONITRATE TABLETS | IMPURITIES | USPNF Online | Online | 26-Apr-2024 | 1-May-2024 | NA | NA | In Organic Impurities/Standard solution: Change isosorbide related compound A to: isosorbide mononitrate related compound A AND In System suitability/Suitability requirements/Relative standard… Read More |
IVERMECTIN | CHEMICAL INFORMATION | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | Change C48H74O14(Component H2B1a) 875.09 C47H72O14(Component H2B1b) 861.07 Component H2B1a: Avermectin… Read More |
LANSOPRAZOLE DELAYED-RELEASE CAPSULES | IMPURITIES/Organic Impurities | USPNF Online | Online | 30-Sep-2022 | 1-Oct-2022 | NA | NA | Delete Blank: Methanol and Diluent (1:9) |
LATANOPROST | ASSAY/Procedure | USPNF Online | Online | 29-Jul-2022 | 1-Dec-2022 | NA | NA | Change Standard solution: Transfer 2.0 mg/mL of USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chromatographic hexane to volume. Sample solution:… Read More |
LEVORPHANOL TARTRATE TABLETS | PERFORMANCE TESTS/Uniformity of Dosage Units 〈905〉 | USPNF Online | Online | 31-Mar-2023 | 1-Aug-2023 | NA | NA | In Sample solution: Change Nominally about 80 ug/mL of levorphanol tartrate in Diluent prepared as follows. to: Nominally about 80 µg/mL of levorphanol tartrate in Diluent prepared as follows. |
LIDOCAINE | ASSAY | USPNF Online | Online | 29-Mar-2024 | 1-Apr-2024 | NA | NA | In Procedure: Change Column: 3.9-mm × 30-cm; 4-µm packing L1 to: Column: 3.9-mm × 30-cm; 10-µm packing L1 |